“Our team continues to make significant strides in the advancement of Ampligen(R) through our active human clinical studies in multiple indications, including pancreatic cancer, ovarian cancer and post-COVID conditions. Our clinical and operational execution is supported by a strong cash position and we are poised for an exciting period ahead as we approach a number of value-driving milestones, particularly in our ovarian and pancreatic cancer programs. We are dedicated to driving our clinical programs forward and building momentum to generate value for our shareholders,” commented Thomas K. Equels, Chief Executive Officer of AIM.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on AIM:
- AIM ImmunoTech Reports Third Quarter 2023 Financial Results and Provides Clinical Pipeline Update
- AIM ImmunoTech Announces Publication of Data from Roswell Park Comprehensive Cancer Center Phase 1 Study Evaluating Ampligen® as a Component of a Chemokine-Modulating (CKM) Regimen in Metastatic Triple-Negative Breast Cancer
- AIM Earnings this Week: How Will it Perform?
- AIM ImmunoTech to Discuss Third Quarter 2023 Financial Results on November 15, 2023 and Host Conference Call and Webcast
- AIM ImmunoTech Announces Encouraging Translational Data from Phase 2 Study Evaluating Ampligen® for the Treatment of Advanced Recurrent Ovarian Cancer
